For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched controlled patient-efficacy study of this exact supplier preparation was verified.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Mechanistic or cellular bioregulator research cannot establish a clinical benefit for this supplier product.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Clinical observation
Pancragen: reported human metabolic observations (2012)
Report includes 30 healthy older adults and 33 people with type 2 diabetes.
Reported findings. The report described lower fasting/challenge glucose, insulin and insulin-resistance measures among recipients.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Abstract does not establish randomization, blinding or detailed allocation. Surrogate markers do not prove diabetes treatment or exact commercial-preparation equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Lab or animal research
[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys].
Five older and five young healthy female rhesus monkeys; older animals compared before/after, with young reference animals.
Reported findings. Glucose-challenge clearance improved in older animals; some effects persisted at three weeks.
Nonresponse. Basal glucose did not change; several insulin/C-peptide findings were nonsignificant trends. One animal had insulin/C-peptide increases rather than decreases, and C-peptide effects did not persist at three weeks.
Harms. Systematic adverse-event and safety assessment not established in the original paper.
Limits. No age-matched vehicle arm, randomization or blinding was described. Abstract normalization language is not uniform benefit across animals or all endpoints. Full article reviewed at the author-uploaded original https://www.researchgate.net/publication/281307252_Impact_of_tetrapeptide_pancragen_on_endocrine_function_of_the_pancreas_in_old_monkeys ; automatic refresh checks original indexed metadata/abstract, not that full-text copy. Healthy nonhuman-primate surrogate outcomes do not establish diabetes treatment in patients.
Preparation: Experimental Lys-Glu-Asp-Trp (KEDW) injection solution; commercial purity, terminal chemistry and preparation equivalence unverified. Route: Intramuscular administration in the animal experiment; not an instruction for human use.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.